Activity of OSE-2101 in HLA-A2+non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial

Giaccone, G.Felip, E.Cobo, M.Garcia Campelo, R.Denis, F.Quoix, E.Madroszyk, A.Debieuvre, D.Hilgers, W.Moran, T.Galetta, D.Romano, G. D.Cappuzzo, F.Robinet, G.Masson, P.Viteri, S.Peled, N.Costantini, D.Dziadziuszko, R.Besse, B.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/26992enActivity of OSE-2101 in HLA-A2+non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trialconference outputopen access10.1016/j.annonc.2020.08.15741569-8041http://www.annalsofoncology.org/article/S0923753420415704/pdf573469101546